Rifaximin: A Comprehensive Review of Structure, Uses, Mechanisms of Action, and Assay Methods

Shibani Raut; Geetanjali Amat; Akshya Kumar Mishra

doi:10.55544/jrasb.3.3.31

Authors

Shibani Raut Department of Pharmaceutical Analysis, GCP, Jamadarpali, Sambalpur, Odisha, INDIA.
Geetanjali Amat Department of Pharmaceutical Analysis, GCP, Jamadarpali, Sambalpur, Odisha, INDIA.
Akshya Kumar Mishra Department of Microbiology, BKCP, Nuapada, Odisha, INDIA.

DOI:

https://doi.org/10.55544/jrasb.3.3.31

Keywords:

Rifaximin, pharmacokinetics, antibiotic, analysis, traveler's diarrhoea

Abstract

Rifaximin, a derivative of rifamycin, has emerged as a promising therapeutic tool in gastroenterology. This review explores rifaximin's intricate molecular structure and pharmacokinetic properties, highlighting its minimal systemic absorption and targeted action within the gut. The multifaceted mechanisms of action, including direct antibacterial effects and modulation of gut microbiota, are discussed. The review then examines the efficacy of rifaximin in treating various gastrointestinal disorders like traveler's diarrhea, Irritable Bowel Syndrome with Diarrhea (IBS-D), and Small Intestinal Bacterial Overgrowth (SIBO). Dosage recommendations and the well-tolerated safety profile of rifaximin are presented. Finally, the importance of quality control measures using techniques like HPLC and spectroscopy is emphasized to ensure the drug's effectiveness and safety.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

"https://pubmed.ncbi.nlm.nih.gov/25095806/"

https://pubchem.ncbi.nlm.nih.gov/compound/Rifaximin-_Xifaxan

Stasi, C., & Baccalà, A. (2016). Rifaximin: Beyond the traditional antibiotic activity. Nature Reviews Gastroenterology & Hepatology, 13(10), 609-616.

Pimentel, M., Lembo, A. J., Chey, W. D., & Lin, H. C. (2014). Rifaximin therapy for irritable bowel syndrome with diarrhea: A systematic review and meta-analysis. Nature Reviews Gastroenterology & Hepatology, 11(8), 530-537.

Ghouri, N. A., Thuluvath, A. J., & Sen, S. (2023). Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database of Systematic Reviews, (2).

Bjornsson, E. S., Sandberg, J., Abrahamsson, H., & Bjorkman, L. (2017). Rifaximin for the treatment of small intestinal bacterial overgrowth: A systematic review and meta-analysis. European Journal of Gastroenterology & Hepatology, 29(12), 1107-1113.

Stanimirova, I., et al. (2008). In vitro activities of rifaximin against anaerobic bacteria from the human intestinal tract. International Journal of Antimicrobial Agents, 31(2), 144-148. https://www.researchgate.net/publication/7991899_Rifaximin_A_nonabsorbed_oral_antibiotic

Ellis, J. P., & Rao, G. R. (2002). Rifaximin: A review of its use in gastrointestinal disorders. Drugs, 62(12), 1709-1722. https://www.ncbi.nlm.nih.gov/books/NBK562329/

Pentimalli, F., et al. (2003). In vitro activity of rifaximin against bacterial strains isolated from patients with traveler's diarrhea. The Journal of Antimicrobial Chemotherapy, 51(1), 103-108. https://www.sciencedirect.com/science/article/pii/S092485791400051X

Pimentel, M., et al. (2009). The cannabinoid receptor CB1 modulates bacterial virulence in a murine model of colitis. American Journal of Physiology-Gastrointestinal and Liver Physiology, 297(5), G829-G838. https://pubmed.ncbi.nlm.nih.gov/35787179/

Ghouri, N., et al. (2014). Rifaximin for irritable bowel syndrome with diarrhea: A systematic review and meta-analysis. The American Journal of Gastroenterology, 109(3), 372-381. https://pubmed.ncbi.nlm.nih.gov/22045120/

DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind clinical trial of rifaximin versus placebo for the treatment of traveler's diarrhea caused by Escherichia coli. The Journal of Antimicrobial Chemotherapy. 2004;54(5):948-954. https://pubmed.ncbi.nlm.nih.gov/15897530/

Travel diarrhoea study group. Rifaximin versus ciprofloxacin for the treatment of traveller's diarrhoea: a randomised, double-blind trial. Lancet Infect Dis. 2005;5(11):703-709. https://pubmed.ncbi.nlm.nih.gov/11692292/

Rifaximin - StatPearls - NCBI Bookshelf National Institutes of Health

Pimentel M, Lagana MM, Mezzi G, Stasi C, Di Mario V, Miele E, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Dig Dis Sci. 2009;54(11):2278-2283. https://pubmed.ncbi.nlm.nih.gov/15963077/

Scarpignato, C., & Pelosini, I. (2005). Rifaximin, a poorly absorbed antibiotic: Pharmacology and clinical use. Chemotherapy, 51(Suppl 1), 36-66.

Jiang, Z.-D., & DuPont, H. L. (2017). Rifaximin: In vitro and in vivo antibacterial activity—a review. Chemotherapy, 63(1), 1-15.

Mullen, K. D., Sanyal, A. J., Bass, N. M., et al. (2014). Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clinical Gastroenterology and Hepatology, 12(8), 1390-1397.

Bass, N. M., Mullen, K. D., Sanyal, A., et al. (2010). Rifaximin treatment in hepatic encephalopathy. New England Journal of Medicine, 362(12), 1071-1081.

Pimentel, M., Lembo, A. J., Chey, W. D., Lin, H. C., Ryu, S. H., & Rao, M. G. (2006). Rifaximin treatment for patients with irritable bowel syndrome with diarrhea: A randomized trial. Journal of the American Medical Association, 295(18), 2178-2185.

Duch, D. S., & Streitwieser, A. (1983). Spectrophotometric and potentiometric determination of the pK_a values of some substituted nitrophenols. Journal of Organic Chemistry, 48(9), 1406-1408.